Zelira Therapeutics Ltd’s (ASX:ZLD) has completed dosing of the last patient in its pioneering medicinal cannabis trial for insomnia.

No serious adverse events have been reported to date during the trial and the company expects to provide interim results by February 2020.

Trial of cannabinoid extract

The insomnia trial is led by the prestigious University of Western Australia Centre for Sleep Science and is evaluating the safety and efficacy of a cannabinoid extract containing THC and CBD in patients with symptoms of clinically diagnosed chronic insomnia.

The primary endpoint of the trial is to assess the impact of full-spectrum cannabis extract on sleep.

An estimated 70 million Americans have insomnia where the market for prescription and over-the-counter medications used to treat the condition generates over US$2 billion in annual revenue.

Zelira is leading the development of clinically validated full-spectrum cannabis medicines to access global markets for insomnia medications.  

Background

Zelira is a leading global therapeutic medicinal cannabis company with access to the world’s largest and fastest-growing cannabis markets.

The company owns a portfolio of proprietary revenue-generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020.

It is currently undertaking:

• Human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the USA; and
• Pre-clinical research examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

Shares have traded up to 5% higher to an intra-day high of 5.8 cents.